Saptalis Pharms Drug Patent Portfolio
Saptalis Pharms owns 1 orange book drug protected by 2 US patents Given below is the list of Saptalis Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541035 | Oral formulations of metronidazole and methods of treating an infection using same | 04 Oct, 2039 | Active |
| US12257236 | Oral formulations of metronidazole and methods of treating an infection using same | 16 Jan, 2039 | Active |
Latest Legal Activities on Saptalis Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Saptalis Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 07 May, 2024 | US11541035 |
| Mail Patent eCofC Notification | 07 May, 2024 | US11541035 |
| Patent eCofC Notification | 07 May, 2024 | US11541035 |
| Recordation of Patent eCertificate of Correction | 07 May, 2024 | US11541035 |
| Mail Certificate of Correction Memo | 17 Apr, 2024 | US11541035 |
| Certificate of Correction Memo | 12 Apr, 2024 | US11541035 |
|
Recordation of Patent Grant Mailed
Critical
| 03 Jan, 2023 | US11541035 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 03 Jan, 2023 | US11541035 |
|
Email Notification
Critical
| 15 Dec, 2022 | US11541035 |
|
Issue Notification Mailed
Critical
| 14 Dec, 2022 | US11541035 |
|
Application Is Considered Ready for Issue
Critical
| 05 Dec, 2022 | US11541035 |
| Dispatch to FDC | 05 Dec, 2022 | US11541035 |
|
Issue Fee Payment Received
Critical
| 30 Nov, 2022 | US11541035 |
|
Issue Fee Payment Verified
Critical
| 30 Nov, 2022 | US11541035 |
|
Electronic Review
Critical
| 02 Sep, 2022 | US11541035 |
Saptalis Pharms's Family Patents
Saptalis Pharms Drug List
Given below is the complete list of Saptalis Pharms's drugs and the patents protecting them.
1. Likmez
Likmez is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541035 | Oral formulations of metronidazole and methods of treating an infection using same |
04 Oct, 2039
(13 years from now)
| Active |
| US12257236 | Oral formulations of metronidazole and methods of treating an infection using same |
16 Jan, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Likmez's drug page